6-Chloro-4-methyl-3-oxo-N-quinuclidin-3-yl-1,4-benzoxazine-8-carboxamide
ADVERTISEMENT
- Molecular formula
- C19H20ClN3O4
- CAS Number
- 2353-75-9
- IUPAC Name
- 6-chloro-4-methyl-3-oxo-N-quinuclidin-3-yl-1,4-benzoxazine-8-carboxamide
- Molecular Weight
- 346.82g/mol
- Melting Point
- (Celsius)
- Boiling Point
- (Celsius)
- Density
- 1.3400g/cm3
- Synonyms
- Azasetron
Identification
Interesting facts
Interesting Facts about 6-Chloro-4-methyl-3-oxo-N-quinuclidin-3-yl-1,4-benzoxazine-8-carboxamide
This compound, often referred to in research and medicinal chemistry, has garnered attention for its intriguing structural features and potential applications. Here are some notable aspects:
- Complex Structure: The presence of a fused benzoxazine ring system makes this compound unique. The combination of the benzene and oxazine moieties contributes to its biological activity.
- Pharmacological Potential: Compounds like this one are being investigated for their role as potential therapeutic agents. Their ability to interact with biological targets suggests they could influence various physiological processes.
- Substituent Influence: The chloro and methyl groups' positions on the ring structure can significantly alter the compound's properties, which is vital for the design of potent analogs in drug development.
- Mechanism of Action: Although not fully elucidated, mechanisms involving receptor modulation or enzyme inhibition are often explored when studying similar compounds, opening avenues for targeted therapies.
- Research Significance: This compound exemplifies how synthetic organic chemistry contributes to discovering new pharmaceutical molecules, showcasing the importance of interdisciplinary approaches in modern science.
As scientists continue to explore the myriad possibilities within such complex compounds, the potential for new discoveries and advancements in the fields of medicinal chemistry and pharmacology remains vast. It highlights the significance of chemical diversity in the quest for effective therapeutics and novel applications.